| 376 | 2 | 204 |
| 下载次数 | 被引频次 | 阅读次数 |
人体感染人类免疫缺陷病毒（Human immunodeficiency virus,HIV）后，虽然抗逆转录病毒疗法（Antiretroviral therapy, ART）可有效控制病毒复制，却无法彻底清除HIV，这主要是由于潜伏病毒库的存在。HIV潜伏库是目前治愈HIV感染的主要挑战，其形成及维持机制是近几年的研究热点，本文从HIV RNA代谢角度探讨HIV潜伏库的形成机制、从细胞克隆扩增方面分析HIV潜伏库的维持机制，并对HIV RNA代谢和克隆扩增途径治愈HIV潜伏库的研究进展进行系统综述，以期为根除潜伏病毒提供新思路。
Abstract：After Human immunodeficiency virus(HIV) infection, although antiretroviral therapy can control viral replication effectively, it cannot eliminate HIV completely, This drawback is due mainly to the existence of “latent viral reservoirs”, which are the main challenge for the cure of HIV infection. The mechanisms underlying formation and maintenance of latent HIV reservoirs(LHRs) have become research “hotspot” in recent years. Herein, we discuss the formation mechanism of LHRs from the perspective of the metabolism of HIV RNA, we analyzed the maintenance mechanism of LHRs from the aspect of cellular clonal expansion, we conducted a systematic review of research progress of curing LHRs by the pathways of HIV RNA metabolism and clonal expansion. Our review can provide new ways of thinking for LHRs eradication.
[1] 2023年第二季度全国艾滋病性病疫情[J].中国艾滋病性病，2023, 29(09):953. DOI:10. 13419/j. cnki.aids. 2023. 09. 01.
[2]邓博文，刘真，李承乘，等. HIV潜伏病毒库清除策略的研究进展[J].中国病原生物学杂志，2023, 18(05):614-618+621. DOI:10. 13350/j. cjpb. 230524.
[3] Cohn LB, Chomont N, Deeks SGet al. The biology of the HIV-1 latent reservoir and implications for cure strategies[J]. Cell Host Microbe, 2020, 27(4):519-530. DOI:10. 1016/j. chom. 2020. 03. 014.
[4] Bruner KM, Wang Z, Simonetti FRet al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses[J]. Nature, 2019, 566(7742):120-125. DOI:10. 1038/s41586-019-0898-8.
[5] Jenabian M A, Costiniuk C T, Mehraj V, et al.Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults[J]. AIDS, 2016, 30(18):2777-2786. DOI:10. 1097/QAD. 0000000000001282.
[6] Whyte-Allman SK, Bendayan R. HIV-1 sanctuary sitesthe role of membrane-associated drug transporters and drug metabolic enzymes[J]. AAPS J, 2020, 22(5):118. DOI:10. 1208/s12248-020-00498-1.
[7] Emery A, Zhou S, Pollom E, et al. Characterizing HIV-1 splicing by using next-generation sequencing[J]. J Virol, 2017, 91(6):e02515-16. DOI:10. 1128/JVI. 02515-16.
[8] Kutluay SB, Emery A, Penumutchu SR, et al. Genome-wide analysis of heterogeneous nuclear ribonucleoprotein(hnRNP)binding to HIV-1 RNA reveals a key role for hnRNP H1 in alternative viral mRNA splicing[J]. J Virol, 2019, 93(21):e01048-19.DOI:10. 1128/JVI. 01048-19.
[9] Moron-Lopez S, Telwatte S, Sarabia I, et al. Human splice factors contribute to latent HIV infection in primary cell models and blood CD4+T cells from ARTtreated individuals[J/OL]. PLoS Pathog, 2020, 16(11):e1009060. DOI:10. 1371/journal. ppat. 1009060.
[10]Mougel M, Akkawi C, Chamontin C, et al. NXF1 and CRM1 nuclear export pathways orchestrate nuclear export, translation and packaging of murine leukaemia retrovirus unspliced RNA[J]. RNA Biol, 2020, 17(4):528-538. DOI:10. 1080/15476286. 2020. 1713539.
[11]Chen J, Umunnakwe C, Sun DQ, et al. Impact of nuclear export pathway on cytoplasmic HIV-1 RNA transport mechanism and distribution[J]. mBio, 2020,11(6):e01578-20. DOI:10. 1128/mBio. 01578-20.
[12]Lassen KG, Ramyar KX, Bailey JR, et al. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+T cells[J/OL]. PLoS Pathog, 2006, 2(7):e68. DOI:10. 1371/journal. ppat. 0020068.
[13]Wang S, Li H, Lian Z, et al. The role of RNA modification in HIV-1 infection[J]. Int J Mol Sci,2022, 23(14):7571. DOI:10. 3390/ijms23147571.
[14]Chen S, Kumar S, Espada CE, et al. N6-methyladenosine modification of HIV-1 RNA suppresses type-I interferon induction in differentiated monocytic cells and primary macrophages[J/OL]. PLoS Pathog,2021, 17(3):e1009421. DOI:10. 1371/journal.ppat. 1009421.
[15]Brisse M, Ly H. Comparative structure and function analysis of the RIG-I-Like receptors:RIG-I and MDA5[J]. Front Immunol, 2019, 10:1586. DOI:10. 3389/fimmu. 2019. 01586.
[16]Han L, Zhuang MW, Deng J, et al. SARS-CoV-2ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways[J]. J Med Virol, 2021, 93(9):5376-5389.DOI:10. 1002/jmv. 27050.
[17]Ringeard M, Marchand V, Decroly E, et al. FTSJ3 is an RNA 2'-O-methyltransferase recruited by HIV to avoid innate immune sensing[J]. Nature, 2019, 565(7740):500-504. DOI:10. 1038/s41586-018-0841-4.
[18]Yamasoba D, Sato K, Ichinose T, et al. N4BP1restricts HIV-1 and its inactivation by MALT1 promotes viral reactivation[J]. Nat Microbiol, 2019, 4(9):1532-1544. DOI:10. 1038/s41564-019-0460-3.
[19]Grau-Expósito J, Luque-Ballesteros L, Navarro J, et al. Latency reversal agents affect differently the latent reservoir present in distinct CD4+T subpopulations[J/OL]. PLoSPathog, 2019, 15(8):e1007991. DOI:10. 1371/journal. ppat. 1007991.
[20]Li M, Kao E, Gao X, et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11[J]. Nature, 2012, 491(7422):125-8. DOI:10. 1038/nature11433.
[21]Su B, Fu Y, Liu Y, et al. Potential application of microrna profiling to the diagnosis and prognosis of HIV-1 infection[J]. Front Microbiol, 2018, 9:3185. DOI:10. 3389/fmicb. 2018. 03185.
[22]Huang J, Wang F, Argyris E, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+T lymphocytes[J]. Nat Med, 2007, 13(10):1241-7. DOI:10. 1038/nm1639.
[23]Elsheikh MM, Tang Y, Li D, et al. Deep latency:A new insight into a functional HIV cure[J].EBioMedicine, 2019, 45:624-629. DOI:10. 1016/j.ebiom. 2019. 06. 020.
[24]Raeber ME, Zurbuchen Y, Impellizzieri D, et al. The role of cytokines in T-cell memory in health and disease[J]. Immunol Rev, 2018, 283(1):176-193. DOI:10. 1111/imr. 12644.
[25]Vandergeeten C, Fromentin R, DaFonseca S, et al.Interleukin-7 promotes HIV persistence during antiretroviral therapy[J]. Blood, 2013, 121(21):4321-9. DOI:10. 1182/blood-2012-11-465625.
[26]Gantner P, Pagliuzza A, Pardons M, et al. Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART[J]. Nat Commun. 2020, 11(1):4089.DOI:10. 1038/s41467-020-17898-8.
[27]Geldmacher C, Ngwenyama N, Schuetz A, et al.Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection[J]. J Exp Med, 2010, 207(13):2869-81. DOI:10. 1084/jem. 20100090.
[28]Singh PK, Bedwell GJ, Engelman AN. Spatial and genomic correlates of HIV-1 integration site targeting[J]. Cells, 2022,11(4):655. DOI:10. 3390/cells11040655.
[29]Shen Q, Wu C, Freniere C, et al. Nuclear import of HIV-1[J]. Viruses, 2021, 13(11):2242. DOI:10. 3390/v13112242.
[30]Lapaillerie D, Lelandais B, Mauro E, et al.Modulation of the intrinsic chromatin binding property of HIV-1 integrase by LEDGF/p75[J]. Nucleic Acids Res, 2021, 49(19):11241-11256. DOI:10. 1093/nar/gkab886.
[31]Achuthan V, Perreira J M, Sowd G A, et al. CapsidCPSF6 interaction licenses nuclear HIV-1 trafficking to sites of viral dna integration[J]. Cell Host Microbe,2018, 24(3):392-404. e8. DOI:10. 1016/j.
[32]Berry CC, Gillet NA, Melamed A, et al. Estimating abundances of retroviral insertion sites from DNA fragment length data[J]. Bioinformatics, 2012, 28(6):755-62. DOI:10. 1093/bioinformatics/bts004.
[33]Wagner T A, McLaughlin S, Garg K, et al.Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection[J]. Science,2014, 345(6196):570-3. DOI:10. 1126/science. 1256304.
[34]35Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, et al. The MYC oncogene-the grand orchestrator of cancer growth and immune evasion[J]. Nat Rev Clin Oncol, 2022,19(1):23-36. DOI:10. 1038/s41571-021-00549-2.
[35]Yeh Y J, Yang K, Razmi A, et al. The clonal expansion dynamics of the HIV-1 reservoir:mechanisms of integration site-dependent proliferation and HIV-1persistence[J]. Viruses, 2021, 13(9):1858. DOI:10. 3390/v13091858.
[36]Cesana D, Santoni de Sio F R, Rudilosso L, et al. HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells[J].Nat Commun, 2017, 8(1):498. DOI:10. 1038/s41467-017-00609-1.
[37]Liu R, Simonetti FR, Ho YC. The forces driving clonal expansion of the HIV-1 latent reservoir[J]. Virol J, 2020, 17(1):4. DOI:10. 1186/s12985-019-1276-8.
[38]Archin N M, Kirchherr J L, Sung J A, et al. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency[J]. J Clin Invest, 2017, 127(8):3126-3135. DOI:10. 1172/JCI92684.
[39]Ahlenstiel C L, Symonds G, Kent S J, et al. Block and Lock HIV cure strategies to control the latent reservoir[J]. Front Cell Infect Microbiol, 2020, 10:424. DOI:10. 3389/fcimb. 2020. 00424.
[40]Long Y, Sou W H, Yung K W Y, et al. Distinct mechanisms govern the phosphorylation of different SR protein splicing factors[J]. J Biol Chem, 2019, 294(4):1312-1327. DOI:10. 1074/jbc. RA118. 003392.
[41]Feng J, Zhou J, Lin Y, et al. HnRNP A1 in RNA metabolism regulation and as a potential therapeutic target[J]. Front Pharmacol. 2022, 13:986409. DOI:10. 3389/fphar. 2022. 986409.
[42]Mueller N, Pasternak A O, Klaver B, et al. The HIV-1 Tat protein enhances splicing at the major splice donor site[J]. J Virol, 2018, 92(14):e01855-17. DOI:10. 1128/JVI. 01855-17.
[43]Kyei G B, Meng S, Ramani R, et al. Splicing Factor3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency[J].mBio, 2018, 9(6):e01423-18. DOI:10. 1128/mBio. 01423-18.
[44]Shkreta L, Blanchette M, Toutant J, et al. Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication[J]. Nucleic Acids Res, 2017, 45(7):4051-4067. DOI:10. 1093/nar/gkw1223.
[45]Lamichhane R, Hammond JA, Pauszek RF, et al. A DEAD-box protein acts through RNA to promote HIV-1Rev-RRE assembly[J]. Nucleic Acids Res, 2017, 45(8):4632-4641. DOI:10. 1093/nar/gkx206.
[46]Prado S, Beltrán M, Morenoá，et al. A smallmolecule inhibitor of HIV-1 Rev function detected by a diversity screen based on RRE-Rev interference[J].Biochem Pharmacol, 2018, 156:68-77. DOI:10. 1016/j. bcp. 2018. 07. 040.
[47]Innis EA, Levinger C, Szaniawski MA, et al.Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence[J]. Biochem Pharmacol, 2021,194:114816. DOI:10. 1016/j.bcp. 2021. 114816. 330
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004554
中图分类号:R512.91
引用信息:
[1]易立政,邓博文,张清燕,等.HIV潜伏库形成与维持机制的研究进展[J].病毒学报,2024,40(05):1173-1179.DOI:10.13242/j.cnki.bingduxuebao.004554.
基金信息:
国家自然科学基金（项目号：82104559）,题目：基于CCL25-CCR9信号通路调节肠淋巴细胞归巢探讨健脾益气方干预HIV/AIDS肠黏膜免疫屏障的作用机制; 河南省重点研发与推广专项课题（项目号：232102311222）,题目：清肺培元方通过抑制中性粒细胞胞外陷阱治疗HIV肺部感染的比较研究; 河南省中医管理局国家中医临床研究基地专项课题（项目号：2021JDZY008）,题目：基于miR124/c-myc信号轴探讨益艾康对HIV/AIDS患者NK细胞的调控作用; 河南省科技攻关（项目号：242102310519）,题目：基与线粒体质量控制介导CD4+T细胞自噬流探讨健脾益气方改善HIV/AIDS患者免疫重建的机制;河南省科技攻关（项目号：242102310314）,题目：基于miR145/CD40信号轴探讨健脾益气方调控HIV潜伏病毒库的作用机制;河南省科技攻关（项目号：232102310462）,题目：益艾康干预HIV病毒储存库调节HIV/AIDS患者免疫功能的疗效评价研究~~
2024-08-01
2024-08-01
2024-08-01